Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H15Cl3N2OS |
Molecular Weight | 437.77 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl
InChI
InChIKey=JLGKQTAYUIMGRK-UHFFFAOYSA-N
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1780 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ERTACZO Approved UseERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section). Launch Date2003 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43.31 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
SERTACONAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395851
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD01AC14
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
||
|
NDF-RT |
N0000008217
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
||
|
NDF-RT |
N0000175487
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
||
|
WHO-ATC |
D01AC14
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
||
|
WHO-ATC |
G01AF19
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2434
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
6008
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
82866
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
99592-32-2
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
C061131
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
72W71I16EG
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
SERTACONAZOLE
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
DTXSID0048551
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
65863
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
DB01153
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201196
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
36435
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
m9874
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084320
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
SUB10497MIG
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
72W71I16EG
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY | |||
|
C75206
Created by
admin on Sat Dec 16 17:27:25 GMT 2023 , Edited by admin on Sat Dec 16 17:27:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)